智通财经APP讯，白云山(00874)公布，近日，公司子公司广州白云山汉方现代药业有限公司(以下简称“白云山汉方”) 收到国家药品监督管理局签发的结构甘油三酯《化学原料药上市申请批准通知书》。
据悉，结构甘油三酯为结构脂肪乳注射液(C6～24)与结构脂肪乳(20%)/ 氨基酸(16)/葡萄糖(13%)注射液等制剂的关键原料。适用于口服或肠内营养摄取不能、不足或禁忌的患者，进行肠外营养补充脂肪。
白云山汉方本次获得结构甘油三酯《化学原料药上市申请批准通知书》，表明该原料药已符合国家相关药品审评技术标准，可进行生产销售，有助于丰富白云山汉方的药用脂质原辅料产品，进一步提升公司脂质原辅料产品的市场竞争力。本次获得《化学原料药上市申请批准通知书》，对公司当期业绩无重大影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.